icon-folder.gif   Conference Reports for NATAP  
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
Safety and Efficacy of Treatment With Interferon-Free, Ribavirin-Free Combination of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naļve Patients With Genotypes 1-6 HCV Infection
  Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Gregory T. Everson,1 Tram T. Tran,2 William J. Towner,3 Mitchell N. Davis,4 David Wyles,5 Ronald Nahass,6 John McNally,7 Diana M. Brainard,7 Lingling Han,7 Brian Doehle,7 Erik Mogalian,7 William T. Symonds,7 John G. McHutchison,7 Tim Morgan,8 Raymond T. Chung9
1University of Colorado Denver, Aurora, USA; 2Cedars-Sinai Medical Center, Los Angeles, CA, USA; 3Kaiser Permanente, Los Angeles, CA, USA; 4Digestive CARE, South Florida Center of Gastroenterology, LLC, Wellington, FL, USA; 5University of California, San Diego, CA, USA; 6ID CARE, Hillsborough, NJ, USA; 7Gilead Sciences, Inc., Foster City, CA, USA; 8VA Long Beach, Long Beach, CA; 9Massachusetts General Hospital, Boston, MA, USA